192 related articles for article (PubMed ID: 24756038)
1. Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line.
Capobianco E; Mora A; La Sala D; Roberti A; Zaki N; Badidi E; Taranta M; Cinti C
PLoS One; 2014; 9(4):e95596. PubMed ID: 24756038
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and miRNA as predictive markers and targets for lung cancer chemotherapy.
El-Awady RA; Hersi F; Al-Tunaiji H; Saleh EM; Abdel-Wahab AH; Al Homssi A; Suhail M; El-Serafi A; Al-Tel T
Cancer Biol Ther; 2015; 16(7):1056-70. PubMed ID: 25962089
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
[TBL] [Abstract][Full Text] [Related]
4. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.
Zhu WG; Otterson GA
Curr Med Chem Anticancer Agents; 2003 May; 3(3):187-99. PubMed ID: 12769777
[TBL] [Abstract][Full Text] [Related]
5. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists.
Mossman D; Kim KT; Scott RJ
BMC Cancer; 2010 Jul; 10():366. PubMed ID: 20618997
[TBL] [Abstract][Full Text] [Related]
6. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
7. Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Zhang YW; Staal B; Dykema KJ; Furge KA; Vande Woude GF
PLoS One; 2012; 7(6):e38955. PubMed ID: 22701735
[TBL] [Abstract][Full Text] [Related]
8. Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.
Xu S; Ren J; Chen HB; Wang Y; Liu Q; Zhang R; Jiang SW; Li J
Curr Pharm Des; 2014; 20(11):1881-7. PubMed ID: 23888960
[TBL] [Abstract][Full Text] [Related]
9. A systems biology approach to identify molecular pathways altered by HDAC inhibition in osteosarcoma.
Wittenburg LA; Ptitsyn AA; Thamm DH
J Cell Biochem; 2012 Mar; 113(3):773-83. PubMed ID: 21976144
[TBL] [Abstract][Full Text] [Related]
10. Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes.
La Sala D; Macaluso M; Trimarchi C; Giordano A; Cinti C
Oncogene; 2003 Jun; 22(23):3518-29. PubMed ID: 12789260
[TBL] [Abstract][Full Text] [Related]
11. Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Teixeira SR; Abreu CM; Parkes L; Davies J; Yao S; Sawhney MA; Margarit L; Gonzalez D; Pinto IM; Francis LW; Conlan RS
Biosens Bioelectron; 2019 Sep; 141():111386. PubMed ID: 31220725
[TBL] [Abstract][Full Text] [Related]
12. Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling.
Foley JM; Scholten DJ; Monks NR; Cherba D; Monsma DJ; Davidson P; Dylewski D; Dykema K; Winn ME; Steensma MR
J Transl Med; 2015 Apr; 13():110. PubMed ID: 25889105
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
14. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
Kim H; Kim SN; Park YS; Kim NH; Han JW; Lee HY; Kim YK
Int J Oncol; 2011 Mar; 38(3):807-12. PubMed ID: 21170509
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic resistance to chemotherapeutic agents in murine osteosarcoma cells.
Takeshita H; Kusuzaki K; Ashihara T; Gebhardt MC; Mankin HJ; Hirasawa Y
J Bone Joint Surg Am; 2000 Jul; 82-A(7):963-9. PubMed ID: 10901311
[TBL] [Abstract][Full Text] [Related]
16. Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells.
Chano T; Mori K; Scotlandi K; Benini S; Lapucci C; Manara MC; Serra M; Picci P; Okabe H; Baldini N
Oncol Rep; 2004 Jun; 11(6):1257-63. PubMed ID: 15138564
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
Zhang Y; Duan G; Feng S
Biochem Biophys Res Commun; 2015 Apr; 459(3):367-73. PubMed ID: 25727016
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas.
Asano N; Takeshima H; Yamashita S; Takamatsu H; Hattori N; Kubo T; Yoshida A; Kobayashi E; Nakayama R; Matsumoto M; Nakamura M; Ichikawa H; Kawai A; Kondo T; Ushijima T
Sci Rep; 2019 Dec; 9(1):20360. PubMed ID: 31889115
[TBL] [Abstract][Full Text] [Related]
19. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
20. Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.
El-Osta A; Kantharidis P; Zalcberg JR; Wolffe AP
Mol Cell Biol; 2002 Mar; 22(6):1844-57. PubMed ID: 11865062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
